SMT C2100: cancer
SMT C2100 is a Seglin being developed for the potential treatment of melanoma and other advanced cancers. Melanoma is one of the most common forms of malignancy with a very poor five year survival rate of less than 20% for advanced disease and no treatments which improve prognosis.
SMT C2100 has shown proof-of-concept in in vivo models of metastatic melanoma working against a novel therapeutic target triggering a specific immunological effect. This effect is to enhance cell mediated killing through the innate immune system, a property which could also be utilised to enhance the therapeutic effect of existing biological cancer treatments such as Avastin and Herceptin.
